|
Market Report
|
Innovations in Injectables: Current and emerging technologies to improve drug delivery
This report evaluates the current and evolving technologies used for injectable drug delivery, the key therapuetic areas, the barriers and driving forces for this market, the competitive landscape is analysed according the technology type, and key pipeline companies and products are examined. Leading companies in the injectable drug delivery market are also profiled.
|
|
Read more...
|
|
|
Market Report
|
The Private Health Insurance Market in Europe: Future trends, emerging opportunities and key players
This report reviews their role in the major European markets and provides an insight into trends in their coverage of health benefits and products. It includes overall trends and profiles of leading insurers, provides an indication of future developments within the sector and highlights potential opportunities for pharmaceutical and diagnostic companies to work with private insurers.
|
|
Read more...
|
|
|
Market Report
|
Analyzing Market Trends and Regulatory Impacts
With fewer truly novel products entering the market, combined with increasing developmental time and spend, and declining ROI, successful launches have never been more important for pharmaceutical companies. Therefore, to ensure a successful launch, manufacturers must employ a multitude of timely strategies to ensure their product enter the market as soon and as smoothly as possible.
|
|
Read more...
|
|
|
Market Report
|
Respiratory syncytial virus, parainfluenza virus and human metapneumovirus as promising new targets
The 2009/10 influenza H1N1 pandemic has boosted awareness of respiratory viral infections. Stockpiling has been pivotal for the strong growth of the influenza antivirals market, with 2009 seven major market sales reaching $1,772m. As the pandemic recedes, other promising targets in the sector include respiratory syncytial virus (RSV), parainfluenza virus (PIV) and human metapneumovirus (hMPV).
|
|
Read more...
|
|
|
Market Report
|
Cystic Fibrosis - A pipeline full of hope
With cystic fibrosis patients still dying prematurely and only two products currently approved for the treatment of this disease, the market is wide open for new entrants. Not only will novel symptomatic treatments and re-formulations lead to improved treatment paradigms, truly disease-modifying compounds are in late-stage development and will significantly change the market.
|
|
Read more...
|
|
|
Market Report
|
Bone building drugs become the heart of the pipeline
Osteoporosis continues to be an attractive therapy area for large pharmaceutical companies due to its high prevalence rate and unmet need. Across the seven major markets, sales for osteoporosis drugs grew with a compound annual growth rate (CAGR) of 2.0% from 2005 to $6.9 billion in 2009. Nonetheless, several promising pipeline drugs will help the market resume growth.
|
|
Read more...
|
|
|
Market Report
|
Market players maximize revenue growth before the next challenging phase
Globally, the osteoporosis market displayed a 3.5% compound annual growth rate (CAGR) between 2005/09, reaching $9.4 billion in 2009. However, the launch of generic alendronate in the majority of markets resulted in a temporary decline in sales during 2009. The market will stabilize during the next 5 years due to generic incursion and then resume growth from 2015 as new drugs are launched.
|
|
Read more...
|
|
|
Market Report
|
|
Targeting Nerve Growth Factor for Pain Therapy - Groundbreaking class to breathe new life into saturated market
Pain treatment is a multibillion dollar market that is saturated with a wide variety of branded and generic drugs. The NGF class has potential to be first of an entirely new type of painkiller to enter the sector in decades. Nevertheless, high expectations need to be tempered once the long term side effects, safety and pharmacoeconomics have been established.
|
|
Read more...
|
|
|
Market Report
|
Fibromyalgia - Regulatory caution threatens EU market expansion
Until regulatory hurdles in the EU are overcome, the US offers the greatest commercial potential and will be the primary growth market for all current and future brands indicated for fibromyalgia. Datamonitor forecasts the fibromyalgia market to more than double in value from 2008 to total $2.5 billion by 2018 across the seven major regions.
|
|
Read more...
|
|
|
Market Report
|
Prostate Cancer - Molecular targeted therapies will fulfill unmet needs in castration-resistant disease
Incidence of prostate cancer in the seven major markets will be just over 422,000 in 2009, indicating high patient potential for drug developers to invest in. There are currently 136 agents in development for prostate cancer, two-thirds of which are novel targeted therapies or immunotherapies. Collectively, the nine drugs in late-phase development are forecast to achieve $2,780m in sales by 2018.
|
|
Read more...
|
|
|
Market Report
|
Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
No therapeutic cancer vaccine has received approval in any of the seven major pharmaceutical markets, despite extensive research efforts. However, with one product in pre-registration in the US, the prospect of the first marketed therapeutic cancer vaccine in the seven major markets is now closer to reality.
|
|
Read more...
|
|
|
Market Report
|
Hepatitis C - High unmet need drives rapid innovation
The Hepatitis C market was worth $2.3 billion in 2007, declining at a CAGR of -2.8% from 2004-2007. Despite this recent slump, Datamonitor forecasts sales to grow to $4.5 billion by 2017, driven primarily by the launch of the new protease inhibitors. The US and EU will remain the largest markets, generating $1.9 billion and $1.7 billion respectively in 2017.
|
|
Read more...
|
|
|
Market Report
|
Hepatitis B & C in Asia - Tapping the opportunity of high prevalence rates in China, Taiwan, South Korea and Turkey
China, Taiwan, South Korea and Turkey represent highly endemic areas for viral Hepatitis. For this report, 180 high-prescribing physicians where surveyed in these countries, providing a breakdown of numbers of treated patients and the most frequently prescribed regimens.
|
|
Read more...
|
|
|
Market Report
|
Global Ophthalmology Devices Market
Global ophthalmology devices and drugs market is witnessing a significant growth due to the increasing incidence and prevalence of eye related disorders such as presbyopia, macular degeneration, and diabetic retinopathy among the aging population. With the introduction of ophthalmic devices equipped with sophisticated technologies, people are increasingly opting for ophthalmic surgeries to correct their eye related disorders.
|
|
Read more...
|
|
|
Market Report
|
Nonalcoholic Steatohepatitis - Drug Pipeline Analysis and Market Forecasts to 2016
GlobalData, the industry analysis specialist's new report, "Nonalcoholic Steatohepatitis (NASH) - Drug Pipeline Analysis and Market Forecasts to 2016" is an essential source of information and analysis on the global nonalcoholic steatohepatitis market. The report identifies the key trends shaping and driving the global nonalcoholic steatohepatitis market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global nonalcoholic steatohepatitis sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData's team of industry experts.
|
|
Read more...
|
|
|
Market Report
|
HIV/AIDS - Drug Pipeline Analysis and Market Forecasts to 2016
GlobalData's report, "HIV/AIDS - Drug Pipeline Analysis and Market Forecasts to 2016" is an essential source of information and analysis on the global HIV/AIDS market. The report identifies the key trends shaping and driving the global HIV/AIDS market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders.
|
|
Read more...
|
|
|
Market Report
|
|
Diagnostic ECG Market (2009 - 2014)
The global diagnostic ECG market is categorized into three submarkets: the rest systems the stress systems and holter systems. These systems are used to measure the electrical activity of the heart. Amongst the three systems, rest system is the most widely-used diagnostic tool. The global market for rest system is expected to grow at a CARG of 9.6% from 2009 to 2014.
|
|
Read more...
|
|
|
Market Report
|
In-Vitro Diagnostics (IVD) Market in BRIC (2010 - 2014)
The IVD markets of BRIC economies offer immense growth opportunities due to the increasing healthcare budgets in these nations, along with the increasing number of private corporate hospitals, and the rising income levels backed by a huge, untapped population bases.
|
|
Read more...
|
|
Farmavita.Net Journal 
